Related Experiment Video
Updated: Jan 31, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
Response to First-line Recurrence Treatment Influences Survival in Hormone Receptor-positive, HER2-negative Breast
Jun Yamamura1,2, Shunji Kamigaki3, Masaki Tsujie3
1Department of Surgery, Sakai City Medical Center, Osaka, Japan june10th68@gmail.com.
Background/Aim:
Little evidence is currently available on significant determinants of post-recurrence survival for patients with hormone receptor-positive (HR+), HER2-negative (HER2-) breast cancer. The objective of this study was to evaluate factors influencing post-recurrence survival in HR+/HER2-breast cancer.
Patients And Methods:
A cohort of 236 patients with recurrent HR+/HER2- breast cancer was retrospectively analyzed to identify significant factors correlating with prognosis after recurrence.
Results:
Multivariate analysis revealed independent prognostic factors of poor survival as follows: short intervals between recurrence and the end of adjuvant endocrine therapy (ET; p=0.046); short disease-free intervals (p=0.019); liver metastasis (p=0.007) or multiple metastases (p<0.001) at recurrence; and a poor response to first-line treatment (p<0.001). A poor first-line treatment response was significantly associated with a shorter response to a subsequent treatment line (p=0.007). Logistic regression analysis indicated that liver metastasis significantly increased the risk of a poor first-line-ET response (p=0.009).
Conclusion:
The first-line treatment response was the key to post-recurrence survival in patients with HR+/HER2- breast cancer. Particularly poor responses led to subsequent unfavorable prognostic outcomes.
Related Concept Videos
Positive, Negative, and Zero Work
Intracellular Hormone Receptors
Types of Hormones
Positive and Negative Feedback Loops
Cancer Survival Analysis
Hormonal Regulation

